Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 222Carcinoma, Non-Small-Cell Lung 219Prostatic Neoplasms 156Multiple Myeloma 142Neoplasms 133Colorectal Neoplasms 118Leukemia, Myeloid, Acute 110Lung Neoplasms 103Neoplasm Metastasis 96Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 86Lymphoma 81Melanoma 78Pancreatic Neoplasms 74Triple Negative Breast Neoplasms 72Ovarian Neoplasms 66Sarcoma 65Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Lymphoma, Non-Hodgkin 55Stomach Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Hematologic Neoplasms 52Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Urinary Bladder Neoplasms 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × 90 days × Clear all
NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis

Phase 2 Active not recruiting
63 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡